Estrogens conjugated, oral
(conjugated estrogenic substances)
Estrogens conjugated, oral (conjugated estrogenic substances) (Premarin)
Conjugated estrogenic substances (Premarin)
Estrogens conjugated
( ES-troh-jens)
Pregnancy Category: X C.E.S. Congest Conjugated Estrogens C.S.D. Premarin (Rx)
Estrogens conjugated, parenteral
Estrogens conjugated, parenteral (Premarin IV)
Estrogens conjugated
Pregnancy Category: X
( ES-troh-jens) Premarin IV (Rx)
Estrogens conjugated, vaginal
Estrogens conjugated, vaginal (Premarin)
Estrogens conjugated
( ES-troh-jens)
Pregnancy Category: X Premarin (Rx)

Classification: Estrogen, natural

See Also: See also Estrogens and Esterified Estrogens .

Action/Kinetics: Contains 50%-65% sodium estrone sulfate and 20%-35% sodium equilin sulfate.

Uses: PO: Moderate to severe vasomotor symptoms due to menopause, atrophic vaginitis, kraurosis vulvae, female hypogonadism, primary ovarian failure, female castration. Palliation in mammary cancer in men or postmenopausal women; prostatic carcinoma (inoperable and progressive). Prophylaxis of osteoporosis.
Parenteral: Abnormal bleeding due to imbalance of hormones and in the absence of disease.

Vaginal: Atrophic vaginitis and kraurosis vulvae associated with menopause.

Special Concerns: Use of estrogen replacement therapy for prolonged periods of time may increase the risk of fatal ovarian cancer and may also have a higher risk of breast cancer.

How Supplied: Estrogens conjugated, oral: Tablet: 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, 2.5 mg. Estrogens conjugated, parenteral: Powder for injection: 25 mg. Estrogens conjugated, vaginal: Cream: 0.625 mg/g

Dosage
•Tablets Moderate to severe vasomotor symptoms due to menopause.
1.25 mg/day given cyclically. If the client has not menstruated in 2 or more months, begin therapy on any day; if, however, the client is menstruating, begin therapy on day 5 of bleeding.
Primary ovarian failure, female castration.
1.25 mg/day given cyclically (3 weeks on, 1 week off). Adjust dose to lowest effective level.
Atrophic vaginitis or kraurosis vulvae associated with menopause.
0.3-1.25 mg/day (higher doses may be necessary, depending on the response) given cyclically (3 weeks on, 1 week off).
Hypogonadism in females.
2.5-7.5 mg/day in divided doses for 20 days, followed by a 10-day rest period. If menses does not occur by the end of this period of time, repeat the dosage schedule. The number of courses of estrogen required to produce bleeding varies, depending on the responsiveness of the endometrium. If bleeding occurs before the end of the 10-day period, start a 20-day estrogen-progestin cycle with 2.5-7.5 mg/day of estrogen with a progestin added the last 5 days. If bleeding occurs before the end of this regimen, discontinue therapy and resume on day 5 of bleeding.
Palliation of mammary carcinoma in men or postmenopausal women.
10 mg t.i.d. for at least 90 days.
Palliation of prostatic carcinoma.
1.25-2.5 mg t.i.d. Effectiveness can be measured by phosphatase determinations and symptomatic improvement.
Prophylaxis of osteoporosis.
0.625 mg/day given cyclically (3 weeks on, 1 week off). Mainstays of therapy include calcium; exercise and nutrition may be important adjuncts.
•IM, IV Abnormal bleeding.
25 mg; repeat after 6-12 hr if necessary.
•Vaginal Cream
1/2-2 g daily given for 3 weeks on and 1 week off. Repeat as needed. Attempt to taper the dose or discontinue the medication at 3- to 6-month intervals.